Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above 200-Day Moving Average – Here’s Why

Posted by Stanley Muller on Sep 5th, 2026

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.10 and traded as high as $4.60. Galectin Therapeutics shares last traded at $4.35, with a volume of 244,140 shares trading hands.

Analyst Ratings Changes

Several analysts have issued reports on GALT shares. Zacks Research upgraded Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Galectin Therapeutics in a report on Tuesday, June 23rd. Weiss Ratings raised shares of Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Galectin Therapeutics presently has an average rating of “Hold” and a consensus price target of $11.00.

Check Out Our Latest Analysis on GALT

Galectin Therapeutics Trading Up 6.0%

The business has a fifty day moving average price of $3.90 and a two-hundred day moving average price of $3.11. The company has a market cap of $303.61 million, a price-to-earnings ratio of -10.72 and a beta of 0.38.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). On average, analysts anticipate that Galectin Therapeutics Inc. will post -0.3 EPS for the current year.

Insiders Place Their Bets

In other Galectin Therapeutics news, Director Harold H. Shlevin sold 22,268 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.04, for a total value of $112,230.72. Following the transaction, the director directly owned 6,500 shares of the company’s stock, valued at $32,760. This represents a 77.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Khurram Jamil sold 47,467 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.04, for a total value of $239,233.68. Following the completion of the transaction, the insider directly owned 2,037 shares in the company, valued at approximately $10,266.48. The trade was a 95.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 89,594 shares of company stock worth $436,703 over the last ninety days. 52.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Galectin Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new stake in Galectin Therapeutics in the first quarter worth approximately $413,000. Lido Advisors LLC acquired a new position in Galectin Therapeutics during the third quarter worth $154,000. Bank of America Corp DE raised its holdings in Galectin Therapeutics by 129.4% during the third quarter. Bank of America Corp DE now owns 25,327 shares of the company’s stock valued at $107,000 after buying an additional 14,285 shares in the last quarter. XTX Topco Ltd raised its holdings in Galectin Therapeutics by 226.6% during the second quarter. XTX Topco Ltd now owns 42,805 shares of the company’s stock valued at $90,000 after buying an additional 29,699 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Galectin Therapeutics in the fourth quarter worth about $90,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

About Galectin Therapeutics

(Get Free Report)

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.